Agilent Technologies (NYSE:A) Issues Q3 Earnings Guidance

Agilent Technologies (NYSE:A – Get Rating) updated its third quarter earnings guidance on Tuesday. The company provided EPS guidance of $1.36-1.38 for the period, compared to the consensus EPS estimate of $1.44. The company issued revenue guidance of $1.640-1.675 billion, compared to the consensus revenue estimate of $1.77 billion. Agilent Technologies also updated its FY23 guidance to $5.60-5.65 EPS.

Agilent Technologies Stock Down 5.9 %

A opened at $120.99 on Thursday. The business’s fifty day simple moving average is $133.87 and its 200 day simple moving average is $144.11. Agilent Technologies has a 52 week low of $112.52 and a 52 week high of $160.26. The firm has a market cap of $35.78 billion, a P/E ratio of 27.31, a PEG ratio of 1.89 and a beta of 1.03. The company has a quick ratio of 1.53, a current ratio of 2.11 and a debt-to-equity ratio of 0.49.

Agilent Technologies (NYSE:A – Get Rating) last posted its quarterly earnings data on Tuesday, May 23rd. The medical research company reported $1.27 EPS for the quarter, beating analysts’ consensus estimates of $1.26 by $0.01. Agilent Technologies had a net margin of 19.09% and a return on equity of 30.35%. The company had revenue of $1.72 billion during the quarter, compared to the consensus estimate of $1.67 billion. During the same quarter in the prior year, the company posted $1.13 EPS. The company’s quarterly revenue was up 6.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Agilent Technologies will post 5.68 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 26th. Shareholders of record on Monday, July 3rd will be given a $0.225 dividend. This represents a $0.90 annualized dividend and a yield of 0.74%. The ex-dividend date is Friday, June 30th. Agilent Technologies’s dividend payout ratio (DPR) is presently 20.32%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on A. Bank of America decreased their price target on Agilent Technologies from $164.00 to $144.00 and set a buy rating for the company in a report on Wednesday. SVB Securities cut their price objective on shares of Agilent Technologies from $170.00 to $145.00 and set an outperform rating on the stock in a report on Wednesday. Evercore ISI cut their price objective on shares of Agilent Technologies from $150.00 to $126.00 and set an outperform rating on the stock in a report on Wednesday. TD Cowen cut their price objective on shares of Agilent Technologies from $168.00 to $145.00 and set an outperform rating on the stock in a report on Wednesday. Finally, Robert W. Baird cut their price objective on shares of Agilent Technologies from $174.00 to $144.00 and set an outperform rating on the stock in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, Agilent Technologies has an average rating of Moderate Buy and an average price target of $151.35.

Hedge Funds Weigh In On Agilent Technologies

Several institutional investors have recently made changes to their positions in A. Synovus Financial Corp raised its holdings in shares of Agilent Technologies by 2.3% during the first quarter. Synovus Financial Corp now owns 6,751 shares of the medical research company’s stock valued at $895,000 after buying an additional 153 shares during the last quarter. Blair William & Co. IL increased its holdings in shares of Agilent Technologies by 7.3% during the first quarter. Blair William & Co. IL now owns 28,606 shares of the medical research company’s stock valued at $3,785,000 after purchasing an additional 1,957 shares during the period. Sequoia Financial Advisors LLC increased its holdings in shares of Agilent Technologies by 52.1% during the first quarter. Sequoia Financial Advisors LLC now owns 2,334 shares of the medical research company’s stock valued at $309,000 after purchasing an additional 799 shares during the period. Vanguard Group Inc. increased its holdings in shares of Agilent Technologies by 1.1% during the first quarter. Vanguard Group Inc. now owns 24,531,170 shares of the medical research company’s stock valued at $3,246,209,000 after purchasing an additional 261,435 shares during the period. Finally, Zions Bancorporation N.A. increased its holdings in shares of Agilent Technologies by 10.8% during the first quarter. Zions Bancorporation N.A. now owns 2,880 shares of the medical research company’s stock valued at $381,000 after purchasing an additional 281 shares during the period.

Agilent Technologies Company Profile

(Get Rating)

Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.